126 related articles for article (PubMed ID: 10234561)
1. Naltrexone effects on short-term and long-term smoking cessation.
Covey LS; Glassman AH; Stetner F
J Addict Dis; 1999; 18(1):31-40. PubMed ID: 10234561
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences.
King A; de Wit H; Riley RC; Cao D; Niaura R; Hatsukami D
Nicotine Tob Res; 2006 Oct; 8(5):671-82. PubMed ID: 17008194
[TBL] [Abstract][Full Text] [Related]
3. The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation.
Walsh Z; Epstein A; Munisamy G; King A
J Addict Dis; 2008; 27(1):65-72. PubMed ID: 18551889
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation.
O'Malley SS; Cooney JL; Krishnan-Sarin S; Dubin JA; McKee SA; Cooney NL; Blakeslee A; Meandzija B; Romano-Dahlgard D; Wu R; Makuch R; Jatlow P
Arch Intern Med; 2006 Mar; 166(6):667-74. PubMed ID: 16567607
[TBL] [Abstract][Full Text] [Related]
5. Naltrexone augments the effects of nicotine replacement therapy in female smokers.
Byars JA; Frost-Pineda K; Jacobs WS; Gold MS
J Addict Dis; 2005; 24(2):49-60. PubMed ID: 15784523
[TBL] [Abstract][Full Text] [Related]
6. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women.
King AC; Cao D; O'Malley SS; Kranzler HR; Cai X; deWit H; Matthews AK; Stachoviak RJ
J Clin Psychopharmacol; 2012 Oct; 32(5):630-6. PubMed ID: 22926596
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of naltrexone on self-injurious behavior.
Sandman CA; Hetrick W; Taylor DV; Marion SD; Touchette P; Barron JL; Martinezzi V; Steinberg RM; Crinella FM
Am J Ment Retard; 2000 Mar; 105(2):103-17. PubMed ID: 10755174
[TBL] [Abstract][Full Text] [Related]
8. Effects on smoking cessation: naltrexone combined with a cognitive behavioral treatment based on the community reinforcement approach.
Roozen HG; Van Beers SE; Weevers HJ; Breteler MH; Willemsen MC; Postmus PE; Kerkhof AJ
Subst Use Misuse; 2006; 41(1):45-60. PubMed ID: 16393735
[TBL] [Abstract][Full Text] [Related]
9. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.
Grant JE; Kim SW; Odlaug BL
Biol Psychiatry; 2009 Apr; 65(7):600-6. PubMed ID: 19217077
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pruritus with topically applied opiate receptor antagonist.
Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients.
Guardia J; Roncero C; Galan J; Gonzalvo B; Burguete T; Casas M
Addict Behav; 2011 Mar; 36(3):265-9. PubMed ID: 21146937
[TBL] [Abstract][Full Text] [Related]
13. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of naltrexone for dissociative symptoms in borderline personality disorder.
Schmahl C; Kleindienst N; Limberger M; Ludäscher P; Mauchnik J; Deibler P; Brünen S; Hiemke C; Lieb K; Herpertz S; Reicherzer M; Berger M; Bohus M
Int Clin Psychopharmacol; 2012 Jan; 27(1):61-8. PubMed ID: 22002175
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
[TBL] [Abstract][Full Text] [Related]
16. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Sharafaddinzadeh N; Moghtaderi A; Kashipazha D; Majdinasab N; Shalbafan B
Mult Scler; 2010 Aug; 16(8):964-9. PubMed ID: 20534644
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.
Malekzad F; Arbabi M; Mohtasham N; Toosi P; Jaberian M; Mohajer M; Mohammadi MR; Roodsari MR; Nasiri S
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):948-50. PubMed ID: 19453814
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone in the treatment of alcohol dependence.
Krystal JH; Cramer JA; Krol WF; Kirk GF; Rosenheck RA;
N Engl J Med; 2001 Dec; 345(24):1734-9. PubMed ID: 11742047
[TBL] [Abstract][Full Text] [Related]
19. Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment.
Lee YS; Joe KH; Sohn IK; Na C; Kee BS; Chae SL
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):639-47. PubMed ID: 15939519
[TBL] [Abstract][Full Text] [Related]
20. Naltrexone and nicotine patch smoking cessation: a preliminary study.
Krishnan-Sarin S; Meandzija B; O'Malley S
Nicotine Tob Res; 2003 Dec; 5(6):851-7. PubMed ID: 14750508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
